Latest Natalizumab Stories
TOORAK, Australia, Sept.
~Convening World's Leading Researchers in MS with a Program Covering all Aspects of Research Including Cause and Pathology, Genetics and Environmental Impact, Emerging Treatment Study Findings and
Biogen Idec's Tecfidera is Forecast to Overtake Teva's Copaxone Franchise as the U.S. Market Leader by 2015, According to Findings from Decision Resources Group BURLINGTON, Mass., Aug.
Genzyme/Sanofi's Lemtrada and Genentech/Roche's Ocrelizumab Will Likely Be Reserved for Patients with Aggressive/Severe MS, According to Findings from Decision Resources Group BURLINGTON, Mass.,
LONDON, June 26, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
CHERRY HILL, N.J., Feb.
MarketReportsOnline.com offers “Global Multiple Sclerosis Market: Trends & Opportunities (2013-18)” research that analyzes the global market sizing and growth of multiple sclerosis in
- A coin originally worth six pennies Scots, and later three; held equivalent to an English halfpenny.
- (in plural) Money; cash.